Literature DB >> 10770643

Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene.

Y Yoshida1, K Tasaki, M Miyauchi, M Narita, K Takenaga, H Yamamoto, T Yaaguchi, H Saisho, S Sakiyama, M Tagawa.   

Abstract

We examined the antitumor effect of locally secreted interleukin (IL)-12 or IL-15 on human pancreatic cancer cells (AsPC-1). We subcutaneously inoculated AsPC-1 cells retrovirally transduced with IL-12 or IL-15 cDNA into nude mice. Tumors derived from these cells showed retarded growth compared with those from wild-type (wt) cells. Nude mice inoculated intraperitoneally with the cytokine producers survived longer than those injected with wt cells. These cytokine producers were also tested for their tumor growth in severe combined immunodeficient mice. The tumor growth of IL-12 producers was similarly suppressed as found in nude mice, but the average tumor volumes of IL-15 producers were not statistically different from those of wt tumors. In nude mice that were administered anti-asialo GM1 antibody before the inoculation of the tumor cells, growth retardation of tumors of IL-12 producers remained the same as in untreated animals, but that of IL-15 producers was markedly reduced. Immunohistochemical analysis revealed that CD11b+ cells migrated into the tumors of cytokine producers and that the number of CD31+ endothelial cells within the tumors was not different between IL-12 producers and wt cells. Taken together with other data, it is possible that granulocytes are candidate cells for the IL-12-mediated antitumor effect, and that natural killer cells and gammadelta T cells are involved in the IL-15-induced antitumor effect. We did not observe synergistic effects of these cytokines to suppress subcutaneous tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770643     DOI: 10.1038/sj.cgt.7700118

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

Review 1.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

2.  IL-15 regulates fibrosis and inflammation in a mouse model of chronic pancreatitis.

Authors:  Murli Manohar; Hemanth Kumar Kandikattu; Alok Kumar Verma; Anil Mishra
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-09-13       Impact factor: 4.052

3.  Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells.

Authors:  Jonas R M Van Audenaerde; Jorrit De Waele; Elly Marcq; Jinthe Van Loenhout; Eva Lion; Johan M J Van den Bergh; Ralf Jesenofsky; Atsushi Masamune; Geert Roeyen; Patrick Pauwels; Filip Lardon; Marc Peeters; Evelien L J Smits
Journal:  Oncotarget       Date:  2017-05-25

4.  Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer.

Authors:  Osmond J D'Cruz; Sanjive Qazi; Larn Hwang; Kevin Ng; Vuong Trieu
Journal:  Onco Targets Ther       Date:  2018-05-14       Impact factor: 4.147

Review 5.  Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects.

Authors:  Ke-Yu Li; Jia-Long Yuan; Diego Trafton; Jian-Xin Wang; Nan Niu; Chun-Hui Yuan; Xu-Bao Liu; Lei Zheng
Journal:  Chronic Dis Transl Med       Date:  2020-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.